arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences

FT Digital Health Summit Europe 2015

London |
Speakers include:
Sir John  Chisholm

Sir John Chisholm

Genomics England

Murray  Stewart

Murray Stewart

GSK

Jessica Federer.

Jessica Federer.

Bayer

Overview

Digital health is reaching a crucial turning point. With a growing array of digitally enabled health applications capturing the public imagination, increasing numbers of consumer brands entering the digital health space, and the industry attracting record levels of investor interest, the stage looks set for the transformation of healthcare delivery models. 

The FT Digital Health Summit Europe brings together leaders from life science and pharmaceutical companies, healthcare providers, technology corporations, investors and regulators to assess how current restrictions to the uptake of digital health can be addressed and also what the roadmaps will look like for healthcare's digital future.

fallback
fallback Add to my Calendar 06/10/2015 08:00:0006/10/2015 18:15:00trueFT Digital Health Summit Europe 2015Digital health is reaching a crucial turning point. With a growing array of digitally enabled health applications capturing the public imagination, increasing numbers of consumer brands entering the digital health space, and the industry attracting record levels of investor interest, the stage looks set for the transformation of healthcare delivery models. The FT Digital Health Summit Europe brings together leaders from life science and pharmaceutical companies, healthcare providers, technology corporations, investors and regulators to assess how current restrictions to the uptake of digital health can be addressed and also what the roadmaps will look like for healthcare's digital future.FT-Digital-Health-Summit-Europe-20152417c691f6d72ae7c10606671157c9dfMM/DD/YYYY

Download the free event brochure

Download now

Speakers (24)

Sir John  Chisholm

Sir John Chisholm

Executive Chair
Genomics England

Sir John is a Cambridge graduate who started work in the automobile industry. His career took flight when he founded CAP Scientific Ltd, which grew rapidly to become a core part of the CAP Group plc and subsequently the Sema Group plc of which he was UK Managing Director. He was then asked by the government to take on the transformation of its defence research laboratories into a commercial organisation. In due course these became an internationally successful technology services company and were floated on the LSE as QinetiQ Group plc of which Sir John became Chairman in 2006. At the same time he was asked to take the Chair of the Medical Research Council. Sir John retired from QinetiQ in February 2010. Sir John is a past president of the IET and holds a number of honorary Doctorates and Fellowships, including the Royal Academy of Engineering. He was knighted in 1999. In April 2015 he was accepted as a director of the Historic Grand Prix Cars Association.

Murray  Stewart

Murray Stewart

Chief Medical Officer
GSK

Murray Stewart is the Chief Medical Officer (CMO) for GlaxoSmithKline (GSK).   As CMO, he provides medical leadership for the Global Medical Organisation at GSK and has primary responsibility for matters of patient safety, medical affairs, medical governance and ethics, medical information and investigations involving human subjects relating to GSK products. Dr Murray joined GSK in 2000 as Associate Director for Clinical Research & Development in the UK.  He subsequently held senior positions in the Cardiovascular and Metabolic therapy area, including Head of

that unit.   He also served as the Clinical Head of the Alternative Development Programme in GSK R&D, and served as clinical lead for GSK’s Biopharm Unit.   Directly prior to his current role, he was Chief Medical Officer, Pharmaceuticals.     

Before joining GSK, Dr Stewart was Honorary Lecturer and Consultant Physician at the Diabetes Centre, Newcastle-upon-Tyne in the UK.  As well as clinical commitments, he also set up diabetes services across the city and ran a research group looking at metabolic abnormalities in relatives of type 2 diabetic patients.  

Dr Murray trained at Southampton Medical School in the UK and is a Fellow of the Royal College of Physicians.

Jessica Federer.

Jessica Federer.

Head of Digital Development
Bayer

Jessica Federer leads digital development at Bayer, a global enterprise advancing Science For A Better Life in the areas of human, animal and plant health. Recognized as one of the top 100 global CDOs and a leading Health Tech Influencer, Federer is passionate about translating digital developments into meaningful public health advancements. Federer previously held positions in Regulatory Affairs, Market Access, Communications and Public Affairs, and worked at the Agency for Healthcare Research and Quality at the US Department of Health and Human Services.

Jessica serves as a Board Member for the MedicAlert Foundation, the UN Agency for Information and Communications Technology (ITU), the World Economic Forum Digital Transformation of Industries Initiative for Chemistry and Advanced Materials, and the Bayer Cares Foundation Committees for both the Employee Volunteer program and the Aspirin Social Innovation Award.

She received a Master of Public Health degree from the Yale School of Public Health, and a Bachelor of Science from The George Washington University. Originally from St. Louis, Missouri, she now lives in Düsseldorf, Germany.

Klaus  Dugi

Klaus Dugi

Senior Vice President Medicine and Chief Medical Officer
Boehringer Ingelheim

Klaus Dugi is Chief Medical Officer and Corporate Senior Vice-President Medicine at Boehringer Ingelheim. His responsibilities include Translational Medicine and Clinical Pharmacology, Clinical Development from First in Man to Registration, Medical Affairs, Clinical Operations, and Biometry and Data Management for Boehringer Ingelheim. During his more than 12 years at BI, Professor Dugi has previously served as Corporate Vice President Medical Affairs and Vice President Therapeutic Area Metabolic Diseases.

Prior to joining Boehringer Ingelheim, he was head of the Metabolic Outpatient Clinic at Heidelberg University Hospital. He qualified in Medicine at Philipps University Marburg and between 1991 and 1996 spent more than four years doing basic and applied biomedical research at the National Institutes of Health in Bethesda, MD, USA. Prior to joining Boehringer Ingelheim, he practiced Internal Medicine and Endocrinology for six years at Heidelberg University Hospital and also conducted clinical and pre-clinical research in the fields of atherosclerosis, diabetes, and lipid metabolism.

Professor Dugi holds a Professorship in Medicine at Heidelberg University and continues to teach general Internal Medicine as well as Endocrinology. He is also member of the Executive Board of Directors of TransCelerate Biopharma.

Pascale Witz

Pascale Witz

Executive Vice President, Global Divisions and Strategic Development
Sanofi

Pascale Witz is the Executive Vice President, Global Divisions & Strategic Development of Sanofi and a Member of its Executive Committee.

She joined Sanofi in 2013 and leadsa portfolio of businesses totaling €15 billion, including Diabetes, Oncology, Immuno-inflammation, Cardiovascular and Consumer Healthcare.

Previously, she worked at GE for 17 years, most recently serving as President & CEO of GE Healthcare’s Medical Diagnostics business. She started her career in research before moving into marketing at Becton Dickinson in 1991.

In 2014, she was listed as one of Fortune’s Most Powerful Women in EMEA. She is also engaged in the Women’s Forum. She holds a Master’s degree in Life Sciences from INSA Lyon and an MBA from INSEAD.

Dhaval Patel

Dhaval Patel

Head, Institute of Biomedical Research Europe
Novartis

Dhavalkumar Patel, based in Basel, Switzerland, is Head of Research Europe and Global Head, Autoimmunity, Transplantation and Inflammation (ATI) Disease Area at the Novartis Institutes for BioMedical Research (NIBR).

Born in India, Dr Patel emigrated to the United States at age seven and obtained a BS in Zoology at Duke University in 1982. Through the Medical Scientist Training Program he earned a PhD from the Department of Microbiology and Immunology as well as a MD from the Duke University School of Medicine in 1989. Dr Patel performed residency training in Internal Medicine and fellowship training in Rheumatology as well as Allergy and Immunology at Duke University Medical Center. He joined the Medicine faculty at Duke where he was Assistant Professor (1994), Associate Professor (1999) and Chief of Allergy and Immunology (2001). In 2003, Dr Patel joined the faculty at the University of North Carolina (UNC) as Professor of Medicine, Professor of Microbiology and Immunology, Chief of the Division of Rheumatology, Allergy and Immunology and Director of the Thurston Arthritis Research Center. He was recognized in 2006 for his contributions by being named the Joseph P Archie, Jr. Eminent Professor of Medicine.

Since 2006, Dr Patel has joined NIBR in Basel, and has held the positions of Head, Fully Integrated Program in Rheumatoid Arthritis; Head, Autoimmunity and Transplantation Research Basel; Global Head, Autoimmunity, Transplantation and Inflammation Disease Area; Head, NIBR Basel; and Head Research Europe.

Dr Patel has a strong background and broad experience in basic and clinical rheumatology, allergy and immunology, having performed scientific work in the areas of cell adhesion/migration and immune reconstitution after bone marrow transplantation. Besides his academic appointments, he is a member of many national and international professional and scientific committees and review boards. Dr Patel has been on five Editorial Boards of journals that focus on research in basic and clinical immunology. He is an author/co-author of more than 100 scientific publications and is also a fellow of the American Academy of Allergy, Asthma and Immunology and of the American College of Rheumatology.

Christofer Toumazou

Christofer Toumazou

Founder and Chief Scientist / Chairman
Institute of Biomedical Engineering, Imperial College / DNA Electronics

Christofer Toumazou’s life work has been dedicated to saving and improving lives through the invention of revolutionary, innovative and disruptive technologies, as well as the creation of a leading edge medical research institute and spin-out ventures to commercialize his ground-breaking inventions, namely DNA Electronics Ltd and Toumaz Group plc.

Professor Toumazou is London’s first Regius Professor of Engineering, at Imperial College London where he holds a Chair in Biomedical Circuits in the Department of Electrical and Electronic Engineering. He is also Director of the Centre for Bio-Inspired Technology, Founder and Chief Scientist of the Institute of Biomedical Engineering, and Chairman of DNA Electronics. DNAe is developing point-of-need diagnostics for life-threatening infectious diseases, based on Professor Toumazou’s semiconductor DNA sequencing technology.  In recognition of this invention he received the European Patent Office’s 2014 European Inventor Award for Research and the Institute of Engineering and Technology’s highest accolade, the Faraday Medal in 2014, and the Royal Society Gabor Medal in 2013. In May 2015 Professor Toumazou was presented with the Institute of Electrical and Electronics Engineers’ Field Medal in Biomedical Engineering for Outstanding Contributions to Biomedical Circuit Technology. 

Pēteris  Zilgalvis

Pēteris Zilgalvis

Head of Unit eHealth and Well Being
DG CONNECT European Commission

Pēteris Zilgalvis is the Head of Unit for eHealth and Well Being in DG CONNECT. He was the Visiting EU Fellow at St. Antony's College, University of Oxford for 2013­14, where he is also an Associate of the Political Economy of Financial Markets Programme. Previously, he was Head of the Governance and Ethics Unit, Directorate Science, Economy and Society at DG Research within the European Commission.

From 1997 to 2005, he was Deputy Head of the Bioethics Department of the Council of Europe, in its Directorate General of Legal Affairs. In addition, he has held various positions in the Latvian civil service within the Ministry of Foreign Affairs and Ministry of Environment. He was Senior Environmental Law Advisor to the World Bank/Russian Federation Environmental Management Project and was Regional Environmental Specialist for the Baltic Countries at the World Bank. 

Pēteris studied political science (cum laude) at the University of California, Los Angeles. At the Law Centre of the University of Southern California he obtained his JD (Doctor of Jurisprudence) and received the Darling Foundation academic scholarship. He completed the High Potentials leadership Programme at Harvard Business School. He is a member of the California State Bar. He has published over 30 publications on bioethics, economics and finance, innovation law and policy, European and environmental law in English, Latvian, and French. A recent publication includes “The Need for an Innovation Principle in Regulatory Impact Assessment: The Case of Finance and Innovation in Europe” in Policy and Internet.

Will  Cavendish

Will Cavendish

Director General, Innovation, Growth and Technology
UK Department of Health

Will Cavendish is Director General of the Department of Health’s Innovation, Growth and Technology Directorate. He is responsible for promoting innovation and technology to bring about a major transformation in health outcomes and in health and care delivery; and supporting innovative and globally competitive health and care sectors, boosting UK jobs and growth.

Prior to this, he was the Director General of the Implementation Group in the Cabinet Office. He led the Implementation Unit which is responsible for implementing the PM and DPM’s top policy priorities, and monitoring and improving policy implementation across the whole of Government; the Open Public Service programme, responsible for the government’s parliament-long programme of public service reform; and the Red Tape Challenge, a pan-Whitehall programme to reduce and improve the stock of regulation on the statute book, thereby meeting the PM’s commitment to leave office having reduced the overall burden of regulation.

Earlier in his career, Will worked in a range of developed and developing countries, including at the World Bank, and has a PhD in Economics. Will has held a number of non-executive positions with organisations including the Specialist Schools and Academies Trust and the Coram Children’s Charity.

Geoff McGrath

Geoff McGrath

Chief Innovation Officer
McLaren Applied Technologies

Geoff McGrath trained as a mechanical engineer, initially working in aeronautical, civil, chemical, petroleum and mechanical engineering. Gaining experience in all aspects of the field, from conceptual engineering through to business development for start-up and blue-chip firms alike, he later switched focus to the world of telecoms, media and entertainment.

He joined McLaren Applied Technologies (MAT) in 2009 and has brought more than 20 years’ experience to bear on the company’s innovative and dynamic approach to pursuing groundbreaking conceptual design, development and engineering.

Dr McGrath is currently focused on developing and applying MAT’s specialist capabilities to a diverse range of subjects in the world of sports, health and wellbeing and strategic operations.

Tony  Young

Tony Young

National Clinical Director for Innovation
NHS England

Tony Young has been a medical innovator and entrepreneur throughout his career. He has established four MedTech companies and raised over £5m in private sector financing for these. He has been a Consultant Urological Surgeon at Southend Hospital since 2007 where his specialist clinical interests include stone disease and laser prostate surgery.

In 2010 he was appointed as Director of Medical Innovation at the Postgraduate Medical Institute at Anglia Ruskin University. This role focuses on transforming the MedTech Innovation process. Professor Young is leading on research, development and commercialisation of new medical devices and developing new educational programmes in this area. Through his role at the PMI he has been instrumental in bringing together the partnership that forms the Anglia Ruskin MedTech Campus. This will become one of the world’s largest health innovation spaces and will help transform the UK MedTech sector.

The MedTech campus brings together all the necessary components of the MedTech innovation process to one place allowing the UK to deliver new MedTech products to market better, faster and smarter than ever before. The development will bring £500m of inward investment into Essex, creating 12,000 new jobs and around 2m sq ft of health innovation space across 120 acres and 3 sites in the county.

In addition to this in the last 4 years Professor Young has been a member of a number of committees/oversight/expert review/task and finish groups for the Department of Health, NHS England, Public Health England, NIHR and Essex County Council. This work has focused on helping to deliver innovation across the NHS.

In September 2014 he was appointed as National Clinical Director for Innovation at NHS England. In this role he provides clinical leadership and support in delivering improved health outcomes across the 5 domains of the NHS outcomes framework. In particular he is focusing on driving the uptake of proven innovations across the NHS, promoting economic growth through innovation and helping to transform the innovation process making the NHS an early adopting straightforward place to do business.

Alexia Tonnel

Alexia Tonnel

Evidence Resources Director
National Institute for Health and Care Excellence

Alexia Tonnel is the Director of Evidence Resources at NICE. She is responsible for ‘NICE Evidence Services’, the suite of digital services, formally known as ‘NHS Evidence’, which provide access to health and care evidence information beyond that produced directly by NICE.

Ms Tonnel also leads the NICE Information Management and Technology team which develops and maintains NICE’s externally and internal facing digital services. Her team also include Information Services, a team of information specialists who search and retrieve the published evidence which will underpin the work of NICE guidance producing centres.

Ms Tonnel studied business and management in France after which she completed a Master of Science in International Accounting and Finance at the London School of Economics and Political Science.

Before joining NICE, she was a Director with Deloitte in London where she advised a range of clients in the healthcare and life science industries on policy and strategy development as well as large programme implementation.

Paul  Zollinger-Read

Paul Zollinger-Read

Chief Medical Officer
Bupa

In July 2012 Paul Zollinger-Read became the Chief Medical Officer of Bupa, where he is responsible for all clinical policies and decisions, including safety and quality, across Bupa’s global businesses. He also leads the newly formed Bupa CMO Network, a group of chief medical officers from some of the world’s largest organisations working in collaboration to improve the health of the world.

Dr. Zollinger-Read studied medicine at Cambridge and then Guy's Hospital, qualifying in 1986. He went on to train as a GP in Oxford before becoming a GP Principle in 1991, until December 2011.

He commenced his NHS management career during the development of Fund Holding and spent some time working with the early NHS Modernisation Agency in 2002. He set up and became CEO of one of the first Care Trusts in the country, merging health and adult social care into one organisation.

He then went on to be the CEO of the neighbouring PCT, Chelmsford, and developed experience of financial and service turnaround.  In the 2006 NHS reorganisation, he was appointed as CEO of North East Essex PCT and was subsequently asked to run Great Yarmouth and Waveney PCT. In 2010 he became CEO of NHS Cambridgeshire and subsequently CEO of NHS Peterborough in 2010.

In 2010 he was also asked to lead the development of GP consortia in the East of England, which expanded to cover the Midlands and East when SHAs clustered in 2012.

In 2011 he joined the King's Fund as Medical Adviser and Primary Care Adviser.

Ger  Brophy

Ger Brophy

Chief Technology Officer
GE Healthcare Life Sciences

Ger Brophy is Chief technology Officer of Life Sciences GE Healthcare; responsible for technology strategy in the Research and Diagnostic tests space. Prior to this Ger was head of New Product Development for Medical Diagnostics in GE Healthcare, responsible for the overarching R&D strategy encompassing in vivo and in vitro diagnostic technologies; overseeing discovery (research) and clinical development; regulatory and medical affairs; project and portfolio management; product acquisition and licensing; R&D efficiency projects and collaborations across GE.

Previously, Ger led Strategic Planning & Licensing within Medical Diagnostics business. He was centrally involved in the expansion of the business into the Personalized Medicine space through inorganic and organic investments in in vitro diagnostics and pathology. Before joining the Medical Diagnostics business, Ger ran the Life Sciences Advanced Systems business in Sweden. The focus on that business was in the commercialization of improved tools for drug discovery. In that capacity he lead an R&D group of 200 researchers developing new products and services used in academia and Pharma to better understand disease. Ger began his career in R&D developing high throughput drug screening tools. He advanced to become Development Director for Amersham's Bioassay's business unit, leading a group of 60 people. Within GE Healthcare he has held positions in Licensing, Business Development and R&D. Ger has had international assignments in the UK, Sweden and in Chicago & New Jersey. He is based in London, UK. Ger holds a Ph.D. in Molecular Biology.

Daniel Mahony

Daniel Mahony

Partner-Healthcare
Polar Capital

Daniel Mahony joined Polar Capital to set up the healthcare team in 2007. He has more than 15 years’ investment experience in the healthcare sector, with over six years as a Portfolio Manager and nine years as a sell-side analyst. Prior to joining Polar Capital, he led the European healthcare research team at Morgan Stanley, covering the European biotechnology, medical technology and healthcare services sectors. He also previously worked in New York for ING Barings Furman Selz following the US biotechnology sector. Before working in the investment field, Mr Mahony worked as a research scientist for seven years with the majority of his time at Schering Plough Corporation in California. He received his PhD from Cambridge University in 1995 and a first class honours degree in biochemistry from Oxford University in 1991.

Francesco Gesualdo

Francesco Gesualdo

Researcher - Telemedicine Unit
Bambino Gesù Children's Hospital

Francesco Gesualdo is a pediatrician working as a researcher at the Bambino Gesù Children's Hospital, Rome, Italy. After years of training through international experiences in Europe and South Africa, he has conducted studies aimed at identifying immunologic features of vaccine preventable diseases.

Recently, Dr Gesualdo’s interests have focused on new technologies applied to the care of children's health. He works in the Telemedicine Unit of his hospital. Dr Gesualdo has conducted a number of surveys aimed at assessing attitude, needs and expectations of health care professionals and families towards telemedicine. On the basis of such data, he is contributing to the development of systems for telemonitoring, integrating a smartphone app with monitoring devices. The projects that Dr Gesualdo is conducting are dedicated to families of children affected with chronic diseases, in particular children with down syndrome, patients affected with asthma and patients carrying subcutaneous ECG monitoring devices.

Moreover, he is conducting studies on the potential of social networks for syndromic surveillance and for informing health promotion campaigns. Aside from his research activity, Dr Gesualdo carries on a daily clinical activity, with a specific focus on counseling regarding breastfeeding, nutrition and vaccinations.

Philipp Gutzwiller

Philipp Gutzwiller

Global Head Healthcare
Lloyds Bank

Philipp Gutzwiller is leading the coverage of global corporate clients in the healthcare sector for Lloyds Bank. He has accumulated over 15 years as a corporate finance advisor and banker to the pharmaceutical industry. Before joining Lloyds Bank, Philipp worked for both bulge-bracket and boutique investment banks with a focus on M&A advisory in the broader healthcare industry. He started his career in the Corporate Finance Division of Roche as a Financial Controller and later worked in the firm’s corporate M&A department. Mr Gutzwiller holds a Master’s Degree in Finance and Economics from the University of Basel, Switzerland.

Mark Duman

Mark Duman

Non-Executive Director, Patient Information Forum
& Director, Intelesant

Mark Duman is a rare blend of clinician, management consultant and patient advocate.  He works with organisations to help them realise the full benefit of their services and products, especially through the often untapped potential of patients and the public.

At the King’s Fund he promoted shared decision making, founded the Ask About Medicines campaign and authored ‘Producing Patient Information’. In the BBC he developed a range of behavioural change interventions to improve people’s health and lifestyle. Following roles in publishing and telecoms, his clients include AstraZeneca, Cancer Research UK, Care Quality Commission, Department of Health, Microsoft, NHS England, Scholl, Tunstall Group and UCB Pharma.

Advisory roles have included the Ministerial Industry Strategy Group on Medicines Access, NHS Alliance People Powered Innovation Group and NHS England’s Insight Strategy Group. He is a Non Executive Director of the Patient Information Forum, and a full time Director at Monmouth Partners Ltd. Mr Duman is a long term condition patient (and advocate) who lives in Manchester, England.

Alexandre Rudoni

Alexandre Rudoni

Partner
Allen & Overy

Alexandre Rudoni is a Partner in the Intellectual Property department at Allen & Overy Paris and heads Allen & Overy’s Life Sciences regulatory practice in Europe.

Mr Rudoni is specialised in intellectual property law, while he also advises on regulatory matters in the Life Sciences sector.  He focuses on the legal and regulatory implications of the interactions between the high tech and life sciences sectors, advising both life sciences clients on digital projects, as well as tech clients investing in the health sector.

Mr Rudoni was seconded to Novartis for six months in 2010, working primarily on digital projects. In 2014, he was named Pharmaceutical Litigation Lawyer of the Year in France by Corporate International Magazine.  

Chris Moore

Chris Moore

Partner, EMEIA Advisory
EY

Chris Moore is the Lead Partner for Life Sciences Advisory in EY in EMEIA focused on providing digital and advanced analytics support through major transformation programmes to clients throughout Europe.

He is the lead partner for Life Sciences Advisory in EY in EMEIA focused on providing strategy and major transformation support to clients throughout Europe. Mr Moore works with large and small organisations around a number of engagements ranging from business strategy to systems implementation. He has worked across the Life Sciences value chain globally for the past 25 years on projects as diverse as the first document management systems in the industry through to clinical re­-design programmes.

He has worked with clients on first of a kind programme to enable analytics to model biological outcomes, assist in better diagnosis, improve drug discovery and improve medicine marketing by outcomes.

His career has seen him build and run the European, Alps and US West Coast Life Sciences practices for IBM, as well as building content management and emerging technology teams for IBM, PwC, Coopers & Lybrand and Kinesis.

Mr Moore is a key contributor towards numerous thought leadership papers and a regular speaker at industry events and forums.

Arthur Franken

Arthur Franken

Partner
Gilde Healthcare

Arthur Franken joined Gilde in 2001. He is focusing on venture and growth capital investments in the biopharm, medtech, diagnostics and digital health sectors. He led the investments in Conatus Pharmaceuticals (IPO on NASDAQ), FlowCardia (acquired by C. R. Bard), Levicept, Moximed, MTM Laboratories (acquired by Roche) and ProQR Therapeutics (IPO on NASDAQ). He has been involved in numerous investments and divestments including Ablynx (IPO on Euronext), Agendia, uniQure (IPO on NASDAQ), BG Medicine (IPO on NASDAQ) and Pieris (IPO on NASDAQ).
Mr Franken represents Gilde on the boards of Levicept, Moximed and Symphogen. He served as a board member for FlowCardia, MTM Laboratories and ProQR Therapeutics until the trade sales or IPO.
Prior to joining Gilde he was active in cardiovascular research at the Leiden/Amsterdam Center for Drug Research and TNO. He holds a masters degree in Biopharmaceutical Sciences from Leiden University, the Netherlands. He is a Dutch national.

Jen Hyatt

Jen Hyatt

Social Tech Entrepreneur and Founder
Big White Wall

Jen Hyatt is a serial social entrepreneur who has founded or helped establish more than 30 social impact organisations in more than 20 countries. She was also a founding member of the Qualitative Research Unit of the UK National Centre for Social Research, and has held various honorary and Board positions including sitting on the Board of International Samaritans and being the Founder and Honorary President of the Balkan Community Initiatives Fund.

Ms Hyatt founded Big White Wall in 2007 and now functions as its Chief Executive. She has twice been named one of the top 50 innovators in healthcare by the Health Service Journal, and was recently selected as a Schwab Foundation Social Entrepreneur of the Year.

She is a thought and practice leader for utilizing technology for person-centered health and social care.

Adlai Goldberg

Adlai Goldberg

Partner, Advisory
EY

Adlai Goldberg is a Partner in EY Switzerland with more than 25 years of digital media, telecommunications and consulting experience. Mr Goldberg helps key international pharmaceutical clients address the challenge of digital. He leads EY’s global social media analytics hub which has answered more than 500 different key strategic questions ranging from changes in legislation to competitive intelligence, customer experience, and more.

Mr Goldberg also leads global health and safety risk assessments for the digital footprints (web, social and mobile) of leading global pharmaceutical companies.

Andrea Mensah

Andrea Mensah

Senior Healthcare Director, EMEA
Oracle

Andrea Mensah is a Senior Director and leads EMEA business development of the Oracle healthcare product portfolio. Ms Mensah is a former management and IT strategy consultant and public sector healthcare IT director. She has 18 years of experience in sectors that include health, life sciences, financial services, real estate, telco and IT.

Previous organisations Ms Mensah has worked for include the NHS, BT, Abbott Laboratories and KPMG. She holds a degree in Genetics and a Master’s degree in Biosystems and Informatics.

fallback

Chaired by (2)

Andrew Ward

Andrew Ward

Energy Editor
Financial Times

Andrew Ward is the FT’s Energy Editor, leading global coverage of the oil and gas industry, power generation and related policy and geopolitical issues. Before taking up his current role in June 2016, Ward was Pharmaceuticals Correspondent, reporting on life sciences, medical technology and healthcare.

Prior to this, Ward was UK News Editor, leading the news desk responsible for the FT’s coverage of UK politics, policy and economics. Previously, Ward served the FT in a number of foreign reporting roles. He was the Nordic bureau chief responsible for coverage of eight countries – Sweden, Norway, Finland, Iceland, Denmark and the three Baltic states of Latvia, Estonia and Lithuania.

Ward has also been the White House correspondent, during which role he covered the George W. Bush administration and the 2008 presidential election campaign. Before moving to Washington, Ward covered business and politics in the US south-east as Atlanta Correspondent. Between 2001 and 2004, he served as Seoul Correspondent, reporting on North and South Korea.

Ward joined the FT in 1999 as a graduate trainee in London and was appointed Media Correspondent in 2000. Ward received his B.A. in Politics and Modern History from the University of Manchester, UK.

Follow Andrew Ward on twitter: @andrew_ward1

Sally Davies

Sally Davies

Digital Editor
Financial Times Weekend

Sally Davies has been covering technology for the Financial Times for the last year, with a special interest in start-ups, artificial intelligence and micro-manufacturing. Previously she worked as a commissioning editor at Nautilus, a New York-based magazine of science and philosophy. Her work has also appeared on the BBC and in The Economist magazine. She qualified as a lawyer in Australia before turning her hand to journalism.

Why Attend?

  • Gain insight into what large-scale investors are looking for when it comes to digital health opportunities
  • Hear how leading life science and pharmaceutical companies are focusing on their strategies for growth within this sector 
  • Meet and hear from senior executives in healthcare organisations looking to invest in new digital solutions 
  • Identify business opportunities within emerging markets’ healthcare delivery systems 
  • Validate the economics of digital health and how consumers are likely to react to its inception
fallback

Agenda - 10th Jun

  • 8:00am
    Registration & networking
  • 9:00am
    Chair’s opening remarks

    Andrew Ward, Pharmaceuticals Correspondent, Financial Times

  • 9:05am
    Leaders Forum: The role of digital health in the wider pharmaceutical, life science and healthcare arena

    It is a crucial time for the digital health community with 2015 being what many are predicting as the ‘industry take-off’ year. Whilst impressive innovation continues to arrive and receive public acceptance, companies are concerned with how national public healthcare systems, regulations and professionals, will be able to successfully incorporate this technology into everyday health and wellness. In order for an effective transition period to take place, the industry must first address the likely challenges to occur. The opening panel of leading stakeholder voices from Europe’s healthcare, life sciences, pharmaceuticals and technology providers will share their various perspectives on this inevitable transition.

    • Where will continued drive in digital health come from? Consumers or the industry? 
    • How will new technologies change the way healthcare data is used and managed? 
    • The role of ‘big data’ in healthcare delivery 
    • Mapping the macro-business trends impacting the digital health ecosystem

    Will Cavendish, Director General – Innovation, Growth and Technology, UK Department of Health
    Sir John Chisholm, Chief Executive Chair, Genomics England
    Jessica Federer, Chief Digital Officer, Bayer
    Pascale Witz, Executive Vice President, Global Divisions and Strategic Development, Sanofi

    Moderated by: Andrew Ward, Pharmaceuticals Correspondent, Financial Times

  • 9:55am
    CMO panel: Incorporating digital innovations into mainstream public healthcare

    Many would argue that the entire healthcare industry is at a crossroads right now. As healthcare becomes more unaffordable and technology continues to capture public imagination, new healthcare delivery models are starting to become available. The whole future delivery system for healthcare is undergoing change and this is due to technology and digital data, but how will public and private healthcare systems react? This panel, featuring industry-leading Chief Medical Officers, will determine the future impact of data and technology when it comes to everyday health care practices.

    • Are healthcare systems now moving closer to the patient? 
    • How long will the traditional face-to-face doctor-patient relationship last? 
    • What’s the likely timeline until patients have dominant control of their own care and their own medical data? 
    • How will medical professionals keep up with constantly changing technological trends? 
    • What opportunities are there for partnerships within healthcare delivery?

    Murray Stewart, Chief Medical Officer, GSK
    Klaus Dugi, Senior Vice President Medicine and Chief Medical Officer, Boehringer Ingelheim
    Paul Zollinger-Read, Chief Medical Officer, Bupa

    Moderated by: Andrew Ward, Pharmaceuticals Correspondent, Financial Times

  • 10:40am
    Morning refreshments
  • 11:05am
    In conversation with

    Andrew Ward, Pharmaceuticals Correspondent, Financial Times interviews Jane Griffiths, Company Group Chairman EMEA, Janssen on her views and strategies on embracing the digital transformation of healthcare from a pharmaceutical perspective

  • 11:25am
    Investment panel: Bridging the gap between venture capital, private equity and investment banking in digital health

    As larger corporations move into the sector and digital data continues to gather pace, it is highly likely that the digital health industry will now start to scale up. Will companies finally be able to crack this market and accelerate growth? If they are then investors will need to play a key role in order to make sure that this growth is scalable and commercial. There has been much start-up innovation in this sector, primarily through venture capitalists that have played significant roles in helping digital health technologies catch the consumer eye but what would the impact be when private equity and investment bankers join the game?

    • Now that leading technology corporations are moving into the digital health space, what interest do investment bankers now have? 
    • How do investors now view the bottom line in light of digital health uptake? 
    • What are the main threats from reimbursement risk? 
    • Which stakeholder sector are investors eyeing up and why?

    Arthur Franken, Partner, Gilde Healthcare
    Philipp Gutzwiller, Head of Healthcare, Lloyds Banking Group
    Daniel Mahony, Fund Manager, Healthcare, Polar Capital

    Moderated by: Andrew Ward, Pharmaceuticals Correspondent, Financial Times

  • 12:10pm
    Panel: The adoption of digital health practices – who will pay for healthcare delivery?

    Digital health will require new payment and business models based on reimbursement in accordance with the value they bring to healthcare services. In some cases, the business model and reimbursement will be based upon finding ways of effectively driving down costs in the healthcare system, often working in collaboration with multiple stockholders. Yet incentives across the system of healthcare are most often misaligned.

    • What are the latest emerging business models? 
    • How can incentives be better aligned? 
    • Identifying examples of organisations that have been successful in gaining reimbursement for digital health enabled services
    • What are payers looking for in their decision making with regards to reimbursement of digital services?

    Alexia Tonnel, Evidence Resources Director, National Institute for Health and Care Excellence
    Mark Duman, Non-Executive Director, Patient Information Forum
    Francesco Gesualdo, Researcher - Telemedicine Unit, Bambino Gesù Children's Hospital
    Adlai Goldberg, Partner, Advisory, EY

    Moderated by: Andrew Ward, Pharmaceuticals Correspondent, Financial Times

  • 12:55pm
    Networking lunch
  • 2:00pm
    Engaging life sciences companies digitally with payers, providers and patients

    Chris Moore, Life Sciences EMEIA Lead Partner, EMEIA Advisory, EY

  • 2:20pm
    Regulation panel: Avoiding the regulatory pitfalls when it comes to digital transformation

    Digital health will inevitably bring with it a whole host of regulatory implications. Forecasting what these implications will be when healthcare migrates onto consumer digital devices will be critical for the effective transition of healthcare services. For example a smart phone can monitor a large range of health conditions but if, due to digital transformation, it turns into a medical device, is it not therefore subject to regulation?

    • Will regulation stifle digital health as has been seen in some other digitalised industries? 
    • How will regulation allow for clarity and growth when it comes to defining what is a medical device and what is a health application? 
    • Can we avoid regulation stumbling in the way of digital health innovation? 
    • How can governments and health services encourage the effective uptake of digital transformation into the health industry?

    Pēteris Zilgalvis, Head of Unit eHealth and Well Being, DG CONNECT European Commission
    Jen Hyatt, Founder and CEO, Big White Wall
    Alexandre Rudoni, Partner, Allen & Overy

    Moderated by: Andrew Ward, Pharmaceuticals Correspondent, Financial Times

  • 3:05pm
    Afternoon refreshments
  • 3:25pm
    Innovation panel: Assessing new technologies in healthcare, pharmaceuticals and biotechnology

    From smart pills to 3D bioprinting, to digestible and wearable sensors to nanorobotics and next generation gene sequencing and beyond, the vast array of technologies under development has the potential to completely transform health and medicine.

    • What are the technologies under development? 
    • Which have the greatest potential for transformation into healthcare services? 
    • Which will make their way into clinical practice? 
    • Can they provide evidence in terms of their usability and their ability to reduce costs in healthcare systems?

    Dirk Voelkel, GM Life Science Technology, GE Healthcare
    Christofer Toumazou, Founder and Chief Scientist / Chairman, Institute of Biomedical Engineering, Imperial College / DNA Electronics
    Tony Young, National Clinical Director for Innovation, NHS England
    Dhaval Patel, Head, Institute of Biomedical Research Europe, Novartis
    Andrea Mensah, Senior Healthcare Director - EMEA, Oracle

    Moderated by: Sally Davies, Digital Editor, Financial Times Weekend

  • 4:20pm
    Closing address and conversation - learning from lessons in digital transformation to ensure healthcare is stable and manageable

    The health sector has been slow compared to other industries in embracing the digital opportunity. Featuring a fifteen minute address followed by a Q&A session with Andrew Ward, this session will bring to light what the health industry can learn in terms of embracing technology, data and analytics, and also the expected challenges ahead.

    Geoff McGrath, Chief Innovation Officer, McLaren Applied Technologies

  • 4:50pm
    Chair’s closing remarks

    Andrew Ward, Pharmaceuticals Correspondent, Financial Times

  • 5:00pm
    Networking drinks reception

Who Attends?

FT Live has a reputation for delivering very senior board level audiences to attend a wide range of world class thought-leadership events across the globe for nearly 40 years. 

The FT Digital Health Summit Europe will be attended by: 

- Pharmaceutical and biotechnology companies 
- Healthcare Providers
- Medical Device manufacturers 
- Health insurers
- Investment banks 
- Hospital Management
- Clinicians 

fallback

Venue

etc.venues St Paul's
200 Aldersgate
London EC1A 4HD

United Kingdom

Tel: +44 (0) 20 3011 0830

fallback

Accommodation

For a map of local accommodation please click the link below:

http://www.hotelmap.com/hotelmap/?pro=M2EKK

fallback

Platinum Sponsor (1)

How EY’s Global Life Sciences Sector can help your business
Life sciences companies — from emerging start-ups to multinational enterprises — face new challenges in a rapidly changing health care ecosystem. Payers and regulators are increasing scrutiny and accelerating the transition to value and outcomes. Big data and patient-empowering technologies are driving new approaches and enabling transparency and consumerism. Players from other sectors are entering health care, making collaborations increasingly complex. These trends challenge every aspect of the life sciences business model, from R&D to marketing. Our Global Life Sciences Sector brings together a worldwide network — more than 7,000 sector-focused assurance, tax, transaction and advisory professionals — to anticipate trends, identify their implications and develop points of view on responding to critical issues. We can help you navigate your way forward and achieve success in the new ecosystem.

Gold Sponsors (2)

At Oracle, we believe that a more predictive, preventive, personalized and participatory system will help improve human health. We can help accelerate this journey to personalized medicine through technology, data and insights. Oracle's solutions support industry initiatives to improve care quality and outcomes, reduce costs, and speed time to market for new treatments, therapies and devices. Oracle Health Sciences delivers comprehensive business applications, plus database, middleware, and hardware solutions for life sciences and healthcare companies and institutions worldwide.

Our ambition at Allen & Overy is to help the world’s leading businesses both maximise the opportunities that globalisation presents and meet the potential challenges. As our clients have sought new markets, so have we, and with 46 offices in 32 countries, our footprint is among the largest of any legal practice.
We have a dedicated global Life Sciences practice comprising of a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, medtech, diagnostics and healthcare sectors. The practice covers the full spectrum of legal support including M&A, commercial transactions, data privacy, IP, capital markets and finance, regulatory and dispute resolution. We follow all key developments in the sector and work with our clients to navigate the legal issues that arise in the context of developing and commercialising digital healthcare offerings.

Supporting Partners (6)

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 33 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

EHTEL is the leading forum for decision makers and doers in Europe, engaged in supporting the transformation of the health care practice in Europe through eHealth. ,EHTEL provides its more than 60 corporate members with a platform for information, representation, networking and co-operation to its 60+ corporate members. EHTEL believes that using ICTs in health and social care in Europe offers an unparalleled opportunity to revolutionise three aspects of services: (1) The quality of health and social care services; (2) The speed and ease of access to these services; and (3) their efficiency and cost effectiveness. The association brings together under one roof a wide range of constituencies crucial for the betterment of health and social care with health IT. They include: National and regional health authorities and systems, Hospitals and other health institutions, Public and private insurance providers, Health professionals, Health managers and executives, Patients, Citizens and consumers, Industry, and Researchers and academics.

The Journal of mHealth is an international publication which brings the latest professional developments in mobile and digital health technologies to healthcare and industry professionals around the world. Featuring, the Latest Industry News, Articles, Research, Industry Whitepapers, Market Reports, and Service Reviews.
The Journal is widely read by healthcare and industry professionals from both North American and European markets, where the publication is a leading resource for anyone with an interest in connected health technologies, applications, devices, and services.

Digital Health Age, Medical Plastics News and European Pharmaceutical Manufacturer are the flagship brands within Rapid News Communications’ Life Sciences division.
www.digitalhealthage.com is the newest addition to the portfolio and is the only website currently addressing the needs of the digital health sector. Its content focuses on personal and professional fitness performance and medical diagnostics as well as providing a community for those involved in the business of the digital healthcare industry.
Medical Plastics News and European Pharmaceutical Manufacturer are established titles in their fields.
Medical Plastics News is the voice of the medical plastics industry and an essential source of business critical, relevant intelligence which stimulates thought leadership and nurtures a connected community of stakeholders.
European Pharmaceutical Manufacturer is a highly regarded brand covering the pharmaceutical manufacturing supply chain from conception to production, keeping readers informed of the latest news, opinions and breakthroughs in this advanced sector.

MedTech Europe is an alliance of European medical technology industry associations. The Alliance was founded by EDMA, representing the European in vitro diagnostic industry, and Eucomed, representing the European medical devices industry. Other European medical technology associations are welcome to join the Alliance, established to represent the common policy interests of its members more effectively and efficiently.
Our mission is to make value-based, innovative medical technology available to more people, while supporting the transformation of healthcare systems onto a sustainable path. We promote a balanced policy environment that enables the medical technology industry to meet the growing healthcare needs and expectations of its stakeholders. In addition, we demonstrate the value of medical technology by encouraging our members to execute the industry’s 5-year strategy.

An international life sciences publishing company, PMGroup’s online focus is PMLiVE.com which hosts its webinars, videos and portfolio of email newsletters and is allied to its dedicated jobs site jobs.pmlive.com.
PMGroup has three print core titles: Pharmaceutical Market Europe (PME) - the monthly magazine for European decision makers and influencers; and the bi-annual publications Communiqué - an essential pharma resource that focuses on PR and medical communications and The Directory of Advertising, Branding, Creative and Digital Agencies in Healthcare, a reference publication for the industry for more than 20 years.
PMGroup’s events portfolio includes The Communiqué Awards, which recognise and commend excellence and best practice in healthcare communications; the Pharmaceutical Market Excellence Awards (PMEA), which focuses on responsible marketing and business practice; and Quality in Care (QiC), which recognise, reward and share good practice and collaboration between the NHS, patient groups and the industry in specific therapy areas.

Organiser (1)

Financial Times Live (FT Live) is the global conferences and events division of the Financial Times Group. Chaired by senior journalists from the Financial Times Group, the summits, conferences, awards and strategic forums organised by FT Live gather the world’s brightest minds and most influential decision-makers.

Exclusive on-stage interviews, stimulating presentations and lively panel debates – available on multiple content platforms – provide the cutting-edge insights, unique personalities and peer audience engagement that have the power to transform finance, business, politics, society and culture.

The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. In 2016 the FT passed a significant milestone in its digital transformation as digital and services revenues overtook print revenues for the first time. The FT has a combined paid print and digital circulation of more than 910,000 and makes 60% of revenues from its journalism.

CONTACT US

Charlie Hayward
Speaking Opportunities
Financial Times
Aneliese Hirst
Marketing And Media Enquiries
Gigs Thoukidides
Sponsorship Opportunities
Financial Times
Funmbi Adenubi
Delegate Booking and Registration Enquiries
Financial Times